Fuji Pharma (4554) · InitiativeRestated
Sustainable contrast media business and competitive injectable manufacturing lines
First written in FY2020. 1 of 3 entries say "Advanced", first in FY2021. Latest entry: FY2022.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Sustainable Contrast Media Business and Competitive Injectable Manufacturing BaseA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「The company will establish a new business model in the contrast media field and build a globally competitive injectable drug production line.」
It continues to pursue the policy of establishing a sustainable contrast media business and building an injectable drug production line with global competitiveness. - FY2021AdvancedAnnual report
「Toyama Plant Injectable drug production equipment ¥3,950 million ¥512 million Internal funds, etc. March 2021 May 2023」
The plan to build a globally competitive injectable drug production line has been specified as injectable drug production equipment at the Toyama Plant, with a total investment of ¥3,950 million and completion scheduled for May 2023. - FY2020First statedAnnual report
「The company will establish a new business model in the contrast media field and build a globally competitive injectable drug production line.」
It newly sets out initiatives to evolve the contrast media business into a sustainable new business model and build an injectable drug production line with global competitiveness.